Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
First Parkinson’s patient dosed in GT-02287 clinical trial - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
First Parkinson’s patient dosed in GT-02287 clinical trial
Parkinson’s News Today
March 19, 2025
First Parkinson’s patient dosed in GT-02287 clinical trial
Related Posts
Post navigation
Previous Post
Gain Therapeutics Doses First Patient in Phase 1b Parkinson’s Trial
Next Post
Webinar: The opportunities in neuroscience drug discovery
Latest Articles
Clear Filters
July 1, 2026
Parkinson’s pipeline pushes beyond dopamine
https://www.biocentury.com/article/659501/parkinson-s-pipeline-pushes-beyond-dopamine?utm_term=profiles.biocentury.com
Read More
June 30, 2026
Gain Therapeutics stock surges on FDA clearance for Parkinson’s drug By Investing.com
https://in.investing.com/news/stock-market-news/gain-therapeutics-stock-surges-on-fda-clearance-for-parkinsons-drug-93CH-5475234
Read More
June 11, 2026
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
https://european-biotechnology.com/latest-news/scenic-biotech-joins-michael-j-fox-lrrk2-consortium-with-a-novel-lysosomal-bet-on-parkinsons/
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles